FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry, specifically to a heterocyclic compound of general formula (I), where (A) denotes phenyl or pyridyl; each (A′), if present, is independently selected from a group consisting of phenyl, phenylC1-C10alkoxy group, phenylC1-C-10alkyl, phenyloxy group and halogen, where each (A′) contains 0, 1, 2 or 3 substitutes independently selected from a group, including halogen, halogenC1-C-10alkyl, phenyl, C1-C10alkyl and C1-C10alkoxy group; X equals 0, 1 or 2; (B) denotes cyclopropyl ring, where (A) and (Z) are covalently bonded to different carbon atoms in (B); (Z) denotes -NH-; (L) is selected from -CH2CH2-, -CH2CH2CH2- and -CH2CH2CH2CH2-; and (D) is selected from -N(-R1)-R2, -O-R3 and -S-R3, where R1 and R2 are bonded to each other, and together with a nitrogen atom to which R1 and R2 are bonded, form a 5- or 6-member heterocyclic ring, where said heterocyclic ring contains 0, 1 or 2 substitutes, independently selected from a group comprising -NH2, -NH(C1-C6-alkyl), -N(C1-C6-alkyl)(C1-C6-alkyl) and C1-C10alkyl, or R1 and R2 are independently selected from a group including -H, C1-C-10alkyl and C3-C7-cycloalkyl, where total number of substitutes in R1 and R2 is equal to 0, 1 or 2 and substitutes are independently selected from -NH2, -NH(C1-C6-alkyl) and -N(C1-C6-alkyl) (C1-C6-alkyl); and R3 denotes C1-C10alkyl; or its enantiomer, diastereomer or mixture thereof, or its pharmaceutically acceptable salt or solvate; provided that following compounds are excluded: N1,N1-dimethyl-N2-(2-phenylcyclopropyl)-1,3-propandiamine and N1,N1-dimethyl-N2-(2-phenylcyclopropyl)-1,2-ethanediamine. Invention also relates to a heterocyclic compound of formula (I'), a pharmaceutical composition based on compound of formula (I) and use of compound of formula (I).
EFFECT: technical result is obtaining novel heterocyclic compounds having activity as a LSD1 inhibitor.
29 cl, 7 dwg, 1 tbl, 40 ex
(I) 
(I')
| Title | Year | Author | Number |
|---|---|---|---|
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2011 |
|
RU2599248C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2681211C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2668952C2 |
| ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | 2011 |
|
RU2611437C2 |
| NOVEL HETEROCYCLIC COMPOUNDS AS BRD4 INHIBITORS | 2016 |
|
RU2721120C2 |
| QUINOLINE COMPOUNDS, METHODS FOR PRODUCTION THEREOF AND USE THEREOF AS MEDICINAL AGENT WHICH INHIBITS URATE TRANSPORTER | 2016 |
|
RU2715229C2 |
| FLUORINATED COMPOUND OF CYCLOPROPYLAMINE, THE METHOD OF PREPARATION, THE PHARMACEUTICAL COMPOSITION AND ITS USE | 2017 |
|
RU2746323C2 |
| AROMATASE INHIBITORS | 2010 |
|
RU2572244C2 |
| N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2010 |
|
RU2607635C2 |
| CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2686117C1 |
